Patents by Inventor Guoquan Wang

Guoquan Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SYSTEM AND METHODS FOR INSERTION AND EDITING OF LARGE NUCLEIC ACID FRAGMENTS
    Publication number: 20240247257
    Abstract: Provided are compositions and methods useful for inserting a larger nucleic acid fragment to a target genome sequence. The editing system employs a pair of pegRNA which, by virtue of their targeting nearby genomic sites and having sequences complementary to each other, collectively form a template for inserting a large exogenous sequence to the target genomic locus.
    Type: Application
    Filed: May 17, 2022
    Publication date: July 25, 2024
    Inventors: Hao YIN, Jinlin WANG, Ying ZHANG, Guoquan WANG, Zhou HE, Ruiwen ZHANG
  • N-ALKYL 2-(DISUBSTITUTED)ALKYNYLADENOSINE-5-URONAMIDES AS A2A AGONISTS
    Publication number: 20190077824
    Abstract: The present invention provides N-alkyl 2-(disubstituted)alkynyladenosine-5?-uronamides and derivatives thereof and pharmaceutical compositions containing the same that are selective agonists of A2A adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.
    Type: Application
    Filed: November 20, 2017
    Publication date: March 14, 2019
    Inventors: Robert D. Thompson, Anthony Beauglehole, Guoquan Wang
  • N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A agonists
    Patent number: 9822141
    Abstract: The present invention provides N-alkyl 2-(disubstituted)alkynyladenosine-5?-uronamides and derivatives thereof and pharmaceutical compositions containing the same that are selective agonists of A2A adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.
    Type: Grant
    Filed: June 27, 2015
    Date of Patent: November 21, 2017
    Assignee: Lewis and Clark Pharmaceuticals, Inc.
    Inventors: Robert D Thompson, Anthony Beauglehole, Guoquan Wang
  • N-ALKYL 2-(DISUBSTITUTED)ALKYNYLADENOSINE-5-URONAMIDES AS A2A AGONISTS
    Publication number: 20170283452
    Abstract: The present invention provides N-alkyl 2-(disubstituted)alkynyladenosine-5?-uronamides and derivatives thereof and pharmaceutical compositions containing the same that are selective agonists of A2A adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.
    Type: Application
    Filed: June 27, 2015
    Publication date: October 5, 2017
    Inventors: Robert D. Thompson, Anthony Beauglehole, Guoquan Wang
  • Xanthine-substituted alkynyl carbamates/reverse carbamates as AB antagonists
    Patent number: 9593118
    Abstract: The present invention provides xanthine-substituted alkynyl carbamates/reverse carbamates and derivatives thereof and pharmaceutical compositions containing the same that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: March 14, 2017
    Assignee: Lewis and Clark Pharmaceuticals, Inc.
    Inventors: Robert D. Thompson, Anthony Beauglehole, Guoquan Wang
  • N-ALKYL 2-(DISUBSTITUTED)ALKYNYLADENOSINE-5-URONAMIDES AS A2A AGONISTS
    Publication number: 20160376302
    Abstract: The present invention provides N-alkyl 2-(disubstituted)alkynyladenosine-5?-uronamides and derivatives thereof and pharmaceutical compositions containing the same that are selective agonists of A2A adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.
    Type: Application
    Filed: June 27, 2015
    Publication date: December 29, 2016
    Inventors: Robert D. Thompson, Anthony Beauglehole, Guoquan Wang
  • XANTHINE-SUBSTITUTED ALKYNYL CARBAMATES/REVERSE CARBAMATES AS A2B ANTAGONISTS
    Publication number: 20160297819
    Abstract: The present invention provides xanthine-substituted alkynyl carbamates/reverse carbamates and derivatives thereof and pharmaceutical compositions containing the same that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.
    Type: Application
    Filed: April 8, 2016
    Publication date: October 13, 2016
    Inventors: Robert D. Thompson, Anthony R. Beauglehole, Guoquan Wang
  • N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as AA agonists
    Patent number: 9067963
    Abstract: The present invention provides N-alkyl 2-(disubstituted)alkynyladenosine-5?-uronamides and derivatives thereof and pharmaceutical compositions containing the same that are selective agonists of A2A adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: June 30, 2015
    Assignee: Lewis and Clark Pharmaceuticals, LLC
    Inventors: Robert D Thompson, Anthony Beauglehole, Guoquan Wang
  • N-ALKYL 2-(DISUBSTITUTED)ALKYNYLADENOSINE-5-URONAMIDES AS A2A AGONISTS
    Publication number: 20140037538
    Abstract: The present invention provides N-alkyl 2-(disubstituted)alkynyladenosine-5?-uronamides and derivatives thereof and pharmaceutical compositions containing the same that are selective agonists of A2A adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.
    Type: Application
    Filed: July 31, 2013
    Publication date: February 6, 2014
    Inventors: Robert D. Thompson, Anthony Beauglehole, Guoquan Wang
  • Methods for the synthesis of unsymmetrical cycloakyl substituted xanthines
    Patent number: 8501941
    Abstract: The present invention provides compounds and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents. Also provided are processes for the preparation of the compounds and their intermediates.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: August 6, 2013
    Assignee: Dogwood Pharmaceuticals, Inc.
    Inventors: Guoquan Wang, Jayson M. Rieger, Robert D. Thompson
  • Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
    Patent number: 8420813
    Abstract: The present invention provides compounds and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents. Also provided are processes for the preparation of the compounds and their intermediates such as: wherein: R2 and R21 are defined in the description.
    Type: Grant
    Filed: July 15, 2009
    Date of Patent: April 16, 2013
    Assignee: Dogwood Pharmaceuticals, Inc.
    Inventors: Guoquan Wang, Jayson M Rieger, Robert Thompson
  • Pyrrolo[3,2-D]pyrimidines that are selective antagonists of Aadenosine receptors
    Patent number: 8349848
    Abstract: The present invention provides compounds of the following formula and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: January 8, 2013
    Assignee: Dogwoof Pharmaceuticals, Inc.
    Inventors: Guoquan Wang, Robert D. Thompson
  • METHODS FOR THE SYNTHESIS OF UNSYMMETRICAL CYCLOAKYL SUBSTITUTED XANTHINES
    Publication number: 20120226040
    Abstract: The present invention provides compounds and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents. Also provided are processes for the preparation of the compounds and their intermediates.
    Type: Application
    Filed: May 17, 2012
    Publication date: September 6, 2012
    Applicant: DOGWOOD PHARMACEUTICALS, INC.
    Inventors: Guoquan WANG, Jayson M. RIEGER, Robert D. THOMPSON
  • Substituted 8-[6-amino-3-pyridyl]xanthines
    Patent number: 8258142
    Abstract: The present invention provides substituted 8-[6-amino-3-pyridyl]xanthines such as the following: and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: September 4, 2012
    Assignee: Dogwood Pharmaceuticals, Inc.
    Inventors: Guoquan Wang, Robert D. Thompson, Jayson M. Rieger
  • Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease
    Patent number: 8193200
    Abstract: The present invention relates to method for treating inflammatory bowel disease that includes administration of an effective amount of an antagonist of A2B adenosine receptors (ARs).
    Type: Grant
    Filed: November 5, 2007
    Date of Patent: June 5, 2012
    Assignees: University of Virginia Patent Foundation, Emory University
    Inventors: Shanthi V. Sitaraman, Joel M. Linden, Guoquan Wang, Robert Douglas Thompson, Jayson M. Rieger
  • Pyrazolyl substituted xanthines
    Patent number: 8153628
    Abstract: The present invention provides compounds and pharmaceutical compositions that are substituted xanthines of formula I: or pharmaceutically acceptable salts thereof, wherein: Z is selected from the group consisting of oxazoyl, isoxazoyl, thiazolyl, and isothiazoyl; and Z1 is a 5-14 member substituted or unsubstituted heteroaryl ring; which are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.
    Type: Grant
    Filed: July 22, 2009
    Date of Patent: April 10, 2012
    Assignee: Forest Laboratories Holdings Limited
    Inventors: Guoquan Wang, Jayson M Rieger, Robert D Thompson
  • SUBSTITUTED 8-[6-AMINO-3-PYRIDYL]XANTHINES
    Publication number: 20110082139
    Abstract: The present invention provides substituted 8-[6-amino-3-pyridyl]xanthines and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.
    Type: Application
    Filed: December 14, 2010
    Publication date: April 7, 2011
    Inventors: Guoquan WANG, Robert D. Thompson, Jayson M. Rieger
  • Substituted 8-[6-amino-3-pyridyl]xanthines
    Patent number: 7884100
    Abstract: The present invention provides substituted 8-[6-amino-3-pyridyl]xanthines like the compound shown in the following formula: and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.
    Type: Grant
    Filed: June 12, 2007
    Date of Patent: February 8, 2011
    Assignee: PGxHealth, LLC
    Inventors: Guoquan Wang, Robert D. Thompson, Jayson M. Rieger
  • Substituted 8-[6-amino-3pyridyl]xanthines
    Patent number: 7875608
    Abstract: The present invention provides substituted 8-[6-amino-3-pyridyl]xanthines like the compound shown in the following formula: and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: January 25, 2011
    Inventors: Robert D. Thompson, Guoquan Wang, Anthony Beauglehole, Frank Schmidtmann
  • SUBSTITUTED 8-HETEROARYL XANTHINES
    Publication number: 20100273780
    Abstract: The present invention provides compounds and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.
    Type: Application
    Filed: April 19, 2010
    Publication date: October 28, 2010
    Applicant: PGXHEALTH, LLC
    Inventors: Guoquan Wang, Jayson M. Rieger, Robert D. Thompson